Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macrogol 3350 (also known as polyethylene glycol 3350) is an osmotic laxative used for the treatment of occasional constipation. It is a synthetic, water-soluble polymer that is not absorbed by the gastrointestinal tract. By retaining water in the bowel through osmotic action, macrogol 3350 increases stool volume and softens the stool, thereby facilitating easier bowel movements and improving gut motility. In Canada, it is marketed under the brand name Lax-A-Day by Norwell Consumer Healthcare (an affiliate of Pharmascience) and Pendopharm, where it is widely recommended by physicians and pharmacists as a gentle, non-stimulant option for constipation relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol 3350.